• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

作者信息

Gisslinger Heinz, Klade Christoph, Georgiev Pencho, Krochmalczyk Dorota, Gercheva-Kyuchukova Liana, Egyed Miklos, Rossiev Viktor, Dulicek Petr, Illes Arpad, Pylypenko Halyna, Sivcheva Lylia, Mayer Jiri, Yablokova Vera, Krejcy Kurt, Hasselbalch Hans C, Kralovics Robert, Kiladjian Jean-Jacques

机构信息

Medical University Vienna, Department of Internal Medicine I, Division of Haematology and Blood Coagulation, Vienna, Austria.

AOP Orphan Pharmaceuticals AG, Vienna, Austria.

出版信息

Hemasphere. 2020 Oct 20;4(6):e485. doi: 10.1097/HS9.0000000000000485. eCollection 2020 Dec.

DOI:10.1097/HS9.0000000000000485
PMID:33134869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7587416/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a4/7587416/2d92e57ba4d5/hs9-4-e485-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a4/7587416/2d92e57ba4d5/hs9-4-e485-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9a4/7587416/2d92e57ba4d5/hs9-4-e485-g002.jpg

相似文献

1
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.聚乙二醇干扰素α-2b：不同年龄组的疗效与安全性
Hemasphere. 2020 Oct 20;4(6):e485. doi: 10.1097/HS9.0000000000000485. eCollection 2020 Dec.
2
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.聚乙二醇干扰素α-2b对比真性红细胞增多症标准疗法（PROUD-PV和CONTINUATION-PV）：一项随机、非劣效性3期试验及其扩展研究。
Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31.
3
Population Pharmacokinetics of Ropeginterferon Alfa-2b: A Comparison Between Healthy Caucasian and Chinese Subjects.聚乙二醇干扰素α-2b的群体药代动力学：健康白种人与中国受试者的比较
Front Pharmacol. 2021 May 28;12:673492. doi: 10.3389/fphar.2021.673492. eCollection 2021.
4
Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.聚乙二醇干扰素α-2b用于真性红细胞增多症患者的治疗。
Drugs Today (Barc). 2020 Mar;56(3):195-202. doi: 10.1358/dot.2020.56.3.3107706.
5
Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.对《聚乙二醇干扰素α-2b治疗日本真性红细胞增多症患者的疗效和安全性：一项开放标签、单臂、2期研究》的勘误
Int J Hematol. 2022 Oct;116(4):642-643. doi: 10.1007/s12185-022-03440-7.
6
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.罗特西普α-2b 在体外和体内靶向 JAK2V617F 阳性真性红细胞增多症细胞。
Blood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0.
7
Ropeginterferon Alfa-2b-njft.聚乙二醇干扰素α-2b-njft
Am J Health Syst Pharm. 2022 Apr 1;79(8):611-615. doi: 10.1093/ajhp/zxac019.
8
Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection.聚乙二醇化干扰素α-2b单药治疗慢性丙型肝炎病毒感染的最佳给药频率
Clin Gastroenterol Hepatol. 2005 Jun;3(6):610-5. doi: 10.1016/s1542-3565(04)00723-2.
9
Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.基于博赛匹韦或特拉匹韦的三联疗法或聚乙二醇干扰素α-2a或α-2b联合利巴韦林双药疗法治疗慢性丙型肝炎的疗效与安全性：真实世界PegBase观察性研究
Ann Gastroenterol. 2017;30(3):327-343. doi: 10.20524/aog.2017.0136. Epub 2017 Mar 23.
10
Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.聚乙二醇干扰素 α-2b 和利巴韦林联合治疗与聚乙二醇干扰素单药治疗在血液透析患者中的疗效和安全性：2 个连续治疗队列的比较。
Am J Kidney Dis. 2013 Oct;62(4):789-95. doi: 10.1053/j.ajkd.2013.03.037. Epub 2013 Jun 5.

引用本文的文献

1
Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes.年轻真性红细胞增多症患者的细胞减灭治疗：安全性和结局的荟萃分析。
Blood Adv. 2024 May 28;8(10):2520-2526. doi: 10.1182/bloodadvances.2023012459.
2
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.真实生活中的细胞减灭治疗：1440 例真性红细胞增多症患者的图表回顾性分析。
J Cancer Res Clin Oncol. 2022 Oct;148(10):2693-2705. doi: 10.1007/s00432-021-03855-5. Epub 2021 Nov 22.
3
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.

本文引用的文献

1
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.聚乙二醇干扰素α-2b对比真性红细胞增多症标准疗法（PROUD-PV和CONTINUATION-PV）：一项随机、非劣效性3期试验及其扩展研究。
Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31.
2
Updates in the management of polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症管理的最新进展。
Ther Adv Hematol. 2019 Aug 30;10:2040620719870052. doi: 10.1177/2040620719870052. eCollection 2019.
3
一项干扰素-α与羟基脲治疗 MPN 的随机试验的基因组分析揭示了突变特异性反应。
Blood Adv. 2022 Apr 12;6(7):2107-2119. doi: 10.1182/bloodadvances.2021004856.
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
罗特西普α-2b 在体外和体内靶向 JAK2V617F 阳性真性红细胞增多症细胞。
Blood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0.
4
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?干扰素-α在治疗真性红细胞增多症和相关骨髓增殖性肿瘤中的作用观点：微小残留病和治愈？
Semin Immunopathol. 2019 Jan;41(1):5-19. doi: 10.1007/s00281-018-0700-2. Epub 2018 Sep 10.
5
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.费城染色体阴性经典骨髓增殖性肿瘤：欧洲白血病网的修订管理建议。
Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27.
6
Polycythemia vera treatment algorithm 2018.真性红细胞增多症治疗算法 2018.
Blood Cancer J. 2018 Jan 10;8(1):3. doi: 10.1038/s41408-017-0042-7.
7
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.NCCN 指南解读：骨髓增殖性肿瘤，第 2.2018 版。
J Natl Compr Canc Netw. 2017 Oct;15(10):1193-1207. doi: 10.6004/jnccn.2017.0157.
8
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.生物制药的聚乙二醇化修饰：已批准药物的化学及非临床安全性信息综述
J Pharm Sci. 2016 Feb;105(2):460-475. doi: 10.1016/j.xphs.2015.11.015.
9
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.聚乙二醇干扰素α-2b，一种新型的干扰素α-2b，在真性红细胞增多症患者中诱导出高缓解率且毒性低。
Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10.
10
Current and future treatment options for polycythemia vera.真性红细胞增多症的当前及未来治疗选择
Ann Hematol. 2015 Jun;94(6):901-10. doi: 10.1007/s00277-015-2357-4. Epub 2015 Apr 2.